Companies › Changchun GeneScience Pharmaceutical
22 active drug programs in 59 registered trials: 22 Phase 2, 20 Phase 1, 13 Phase 3, 4 Phase 4; Oncology, Metabolic and endocrine, Other, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Megestrol Acetate Progesterone receptor agonist | PGR | Phase 4 | Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia; Non-small Cell Lung Cancer; Neoadjuvant Chemotherapy; Nutrition Disorders … | Dec 2026 |
| Somatropin Growth hormone receptor agonist | GHR | Phase 4 | Short Bowel Syndrome (SBS) in Adults; Short Stature Children Born Small for Gestational Age (SGA); Dwarfism; Healthy … | Apr 2027 |
| Cabergoline Dopamine D2 receptor agonist | DRD2 | Phase 3 | Hyperprolactinemia; Prolactinoma; Pituitary Neoplasms; Gynecologic Disease … | Nov 2026 |
| Leuprolide Gonadotropin-releasing hormone receptor agonist | GNRHR | Phase 3 | Breast Cancer Subjects | – |
| PEG-rhGH Injection (Jintrolong®) Recombinant human growth hormone with polyethylene glycol modification for extended half-l | GH1 | Phase 2 | Short Stature Children Born Small for Gestational Age (SGA) | Dec 2026 |
| GenSci120 150 mg | – | Phase 2 | Rheumatoid Arthritis | Sep 2027 |
| GenSci048 | – | Phase 2 | Uveitis; Endometriosis-related Pain | Dec 2027 |
| Genakumab injection CXCL10 inhibitor monoclonal antibody | CXCL10 | Phase 2 | Systemic Sclerosis Associated Interstitial Lung Disease | – |
| GenSci134 Growth hormone secretagogue (based on context of AGHD indication) | – | Phase 1 | Safety | Nov 2026 |
| GenSci144 tablets SLC6A19 transporter small molecule inhibitor | SLC6A19 | Phase 1 | Phenylketonuria | Dec 2026 |
| [14C]GS1-144 | – | Phase 1 | Healthy Postmenopausal Women | Dec 2026 |
| GenSci142 | – | Phase 1 | Randomized | Jan 2027 |
| GenSci136 | – | Phase 1 | Autoimmune Disease | Feb 2027 |
| GenSci098 | – | Phase 1 | Safety | Mar 2027 |
| GenSci161 | – | Phase 1 | Healthy Volunteers | May 2027 |
| GenSci128 TP53 Y220C mutant stabilizer | TP53 | Phase 1 | Solid Tumors Harboring a TP53 Y220C Mutation | Dec 2027 |
| GenSci140 Folate receptor alpha (FRα) targeting agent for FRα-positive advanced solid tumors | FOLR1 | Phase 1 | Advanced Solid Tumors | Mar 2028 |
| GenSci139 bispecific antibody drug conjugate targeting EGFR and HER2 | EGFR, HER2 | Phase 1 | Advanced Solid Tumors | Jul 2028 |
| GenSci143 for injection | – | Phase 1 | Advanced Solid Tumors | Oct 2028 |
| GenSci145 PIK3CA inhibitor | PIK3CA | Phase 1 | Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated | Nov 2028 |
| GenSci122 | – | Phase 1 | Advanced Solid Tumor | Dec 2028 |
| GS3-007a dry suspension Growth hormone secretagogue | – | Phase 1 | Healthy Adults; Pediatric Growth Hormone Deficiency | Nov 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02375620 | Somatropin | Phase 2 | Short Stature Children Born Small for Gestational Age (SGA) | Other | Dec 2023 |
| NCT04576104 | Megestrol Acetate | Phase 2 | Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | Oncology | Aug 2025 |
| NCT06449027 | Leuprolide | Phase 3 | Breast Cancer Subjects | Oncology | Nov 2025 |
| NCT07008417 | Cabergoline | Phase 1 | Hyperprolactinemia | Metabolic and endocrine | Feb 2026 |
| NCT06189495 | Genakumab injection | Phase 2 | Systemic Sclerosis Associated Interstitial Lung Disease | Immunology | Mar 2026 |
| NCT07473570 | GS3-007a dry suspension | Phase 1 | Healthy Adults | Other | May 2026 |
| NCT07040930 | GenSci120 150 mg | Phase 1 | Rheumatoid Arthritis | Immunology | Jul 2026 |
| NCT07323329 | Somatropin | Phase 2 | Infertility | Genitourinary | Nov 2026 |
| NCT07043322 | Cabergoline | Phase 2 | Gynecologic Disease | Other | Nov 2026 |
| NCT07124221 | Cabergoline | Phase 3 | Hyperprolactinemia | Metabolic and endocrine | Nov 2026 |
| NCT07016802 | GenSci134 | Phase 1 | Safety | Metabolic and endocrine | Nov 2026 |
| NCT07338487 | Megestrol Acetate | Phase 1 | Locally Advanced Cervical Cancer | Oncology | Dec 2026 |
| NCT02288962 | Cabergoline | Phase 3 | Pituitary Neoplasms | Oncology | Dec 2026 |
| NCT05355272 | Somatropin | Phase 2 | Gulf War Syndrome | Metabolic and endocrine | Dec 2026 |
| NCT07685210 | GenSci144 tablets | Phase 1 | Phenylketonuria | Metabolic and endocrine | Dec 2026 |
| NCT07260500 | PEG-rhGH Injection (Jintrolong®) | Phase 2 | Short Stature Children Born Small for Gestational Age (SGA) | Other | Dec 2026 |
| NCT05447208 | Somatropin | Phase 3 | Preimplantation Genetic Testing | Metabolic and endocrine | Dec 2026 |
| NCT07243379 | Megestrol Acetate | Phase 4 | Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia | Oncology | Dec 2026 |
| NCT07537231 | [14C]GS1-144 | Phase 1 | Healthy Postmenopausal Women | Metabolic and endocrine | Dec 2026 |
| NCT07663838 | GenSci142 | Phase 1 | Randomized | Infectious disease | Jan 2027 |
| NCT07366866 | GenSci136 | Phase 1 | Autoimmune Disease | Immunology | Feb 2027 |
| NCT04867317 | Somatropin | Phase 3 | Adult Growth Hormone Deficiency | Neurology | Feb 2027 |
| NCT05316493 | Megestrol Acetate | Phase 2 | Atypical Endometrial Hyperplasia | Metabolic and endocrine | Feb 2027 |
| NCT03671811 | Megestrol Acetate | Phase 2 | Atypical Endometrial Hyperplasia | Oncology | Feb 2027 |
| NCT07286656 | GenSci098 | Phase 1 | Safety | Metabolic and endocrine | Mar 2027 |
| NCT07691125 | Somatropin | Phase 4 | Short Bowel Syndrome (SBS) in Adults | Gastroenterology | Apr 2027 |
| NCT07476586 | GenSci161 | Phase 1 | Healthy Volunteers | Other | May 2027 |
| NCT06998758 | Megestrol Acetate | Phase 3 | Neoadjuvant Chemotherapy | Metabolic and endocrine | May 2027 |
| NCT06500234 | Megestrol Acetate | Phase 3 | Nutrition Disorders | Oncology | May 2027 |
| NCT05913427 | Megestrol Acetate | Phase 2 | Adrenocortical Carcinoma | Oncology | Jun 2027 |
| NCT07150663 | Megestrol Acetate | Phase 3 | Non-small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT07463235 | Cabergoline | Phase 3 | Prolactinoma | Oncology | Aug 2027 |
| NCT06569758 | GenSci098 | Phase 1 | Safety | Ophthalmology | Sep 2027 |
| NCT07423533 | GenSci120 150 mg | Phase 2 | Rheumatoid Arthritis | Immunology | Sep 2027 |
| NCT07423533 | GenSci120 150 mg | Phase 2 | Rheumatoid Arthritis | Immunology | Sep 2027 |
| NCT07423533 | GenSci120 150 mg | Phase 2 | Rheumatoid Arthritis | Immunology | Sep 2027 |
| NCT07796789 | Megestrol Acetate | Phase 3 | Nasopharyngeal Cancinoma (NPC) | Oncology | Sep 2027 |
| NCT07547995 | GenSci048 | Phase 2 | Uveitis | Ophthalmology | Dec 2027 |
| NCT06908434 | GenSci128 | Phase 1 | Solid Tumors Harboring a TP53 Y220C Mutation | Oncology | Dec 2027 |
| NCT07319429 | Megestrol Acetate | Phase 2 | Endometrial Cancer | Oncology | Dec 2027 |
| NCT06103513 | Somatropin | Phase 3 | Growth Disorders | Metabolic and endocrine | Jan 2028 |
| NCT07492160 | Cabergoline | Phase 2 | Pregnancy | Other | Feb 2028 |
| NCT07072910 | Cabergoline | Phase 2 | Migraine | Neurology | Mar 2028 |
| NCT07072910 | Cabergoline | Phase 2 | Migraine | Neurology | Mar 2028 |
| NCT07251166 | GenSci140 | Phase 1 | Advanced Solid Tumors | Oncology | Mar 2028 |
| NCT05681299 | Somatropin | Phase 4 | Healthy | Metabolic and endocrine | Apr 2028 |
| NCT06963177 | GenSci048 | Phase 2 | Endometriosis-related Pain | Genitourinary | May 2028 |
| NCT07230977 | GenSci139 | Phase 1 | Advanced Solid Tumors | Oncology | Jul 2028 |
| NCT07036003 | Somatropin | Phase 1 | Knee Osteoarthritis (Knee OA) | Immunology | Jul 2028 |
| NCT05382637 | Somatropin | Phase 2 | Growth Disorders | Metabolic and endocrine | Sep 2028 |
| NCT07252414 | GenSci143 for injection | Phase 1 | Advanced Solid Tumors | Oncology | Oct 2028 |
| NCT07407504 | GenSci145 | Phase 1 | Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated | Oncology | Nov 2028 |
| NCT06772415 | GenSci122 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2028 |
| NCT07543536 | Megestrol Acetate | Phase 3 | Advanced/Metastatic Breast Cancer | Oncology | Apr 2029 |
| NCT07045935 | Cabergoline | Phase 4 | Prolactinoma | Oncology | Dec 2029 |
| NCT03255694 | Somatropin | Phase 2 | Dwarfism | Metabolic and endocrine | Jun 2030 |
| NCT07436793 | Megestrol Acetate | Phase 2 | Endometrial Endometrioid Adenocarcinoma | Oncology | Jun 2030 |
| NCT07264595 | GS3-007a dry suspension | Phase 1 | Pediatric Growth Hormone Deficiency | Metabolic and endocrine | Nov 2030 |
| NCT07831902 | Megestrol Acetate | Phase 3 | Endometrial Cancer | Oncology | Dec 2030 |
Hangzhou Zhongmei Huadong Pharmaceutical Jiangsu Hansoh Pharmaceutical Yuhan Haisco Pharmaceutical Group Sichuan Baili Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.